Filing Flows › Beta Bionics (BBNX) › Guidance & outlook
Beta Bionics (BBNX) guidance and outlook
Beta Bionics (BBNX) reaffirmed its guidance on Oct 27, 2026: Revenue (segment) $8.5M for Q4 2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | Q4 2026 | $8.5M | new |
From the earnings release filed Oct 27, 2026 (8-K on EDGAR).
Beta Bionics' latest quarter
Beta Bionics, Q3 2026: revenue $35.5M (+30% year over year), operating margin -74.9%, net loss $24.4M, operating cash flow −$12.3M. The chart follows the revenue to costs, profit and cash.
Questions
Did Beta Bionics raise or lower its guidance?
Beta Bionics (BBNX) reaffirmed its guidance on Oct 27, 2026: Revenue (segment) $8.5M for Q4 2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.